Cytokinetics, Incorporated (CYTK)

Nasdaq · Healthcare · Biotechnology
$50.78-1.32%As of 2026-11-22 · USD
Last session low $50.60Last session high $53.38
52-week low $50.3252-week high $88.31
Market cap
$7.07B
Sector
Healthcare

Market data and research context for informational purposes. Not investment advice.

Technical indicators

Indicators from the 2026-11-20 daily bar; Bollinger %B and the average rows compare the latest price with those values. Prices in USD.

IndicatorValueReading
RSI (14)30.7In the neutral range (30 to 70)
MACD (12, 26, 9)-3.18Below its signal line (-2.70); histogram -0.48
Bollinger %B (20, 2)12%Inside the bands (48.69 to 66.13)
SMA 2057.41Price is 11.5% below
SMA 5061.90Price is 18.0% below
SMA 20069.49Price is 26.9% below
ATR (20)5.08% of priceAverage true range per day
52-week position1%In the lower part of the 50.32 to 88.31 range

About Cytokinetics, Incorporated

Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM.

Insider filings, 90 daysNo purchases and 16 sales (about $11.9M).
Latest fiscal yearEnded 2025-12-31: revenue of $88.04M and an operating margin of -695.4%.

More in Biotechnology